0001493152-24-011627.txt : 20240328 0001493152-24-011627.hdr.sgml : 20240328 20240328090531 ACCESSION NUMBER: 0001493152-24-011627 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240328 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pulmatrix, Inc. CENTRAL INDEX KEY: 0001574235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461821392 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36199 FILM NUMBER: 24793899 BUSINESS ADDRESS: STREET 1: 36 CROSBY DRIVE STREET 2: SUITE 100 CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: (781) 357-2333 MAIL ADDRESS: STREET 1: 36 CROSBY DRIVE STREET 2: SUITE 100 CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: Ruthigen, Inc. DATE OF NAME CHANGE: 20130411 8-K 1 form8-k.htm
false 0001574235 0001574235 2024-03-28 2024-03-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 28, 2024

 

 

 

PULMATRIX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36199   46-1821392

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

36 Crosby Drive, Suite 100

Bedford, MA 01730

(Address of principal executive offices) (Zip Code)

 

(781) 357-2333

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  

Name of exchange

on which registered

Common Stock, par value $0.0001 per share   PULM   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 28, 2024, Pulmatrix, Inc. issued a press release announcing its financial results for the fourth fiscal quarter and twelve months ended December 31, 2023, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release dated March 28, 2024*
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

* This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be “filed.”

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PULMATRIX, INC.
     
Date: March 28, 2024 By: /s/ Teofilo Raad
    Teofilo Raad
    Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibti 99.1

 

 

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

 

2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026

 

3rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study and a significant reduction in expected cash burn for Pulmatrix

 

Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix

 

Bedford, Mass., March 28, 2024 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2023 and provided a corporate update on its development programs.

 

Ted Raad, Chief Executive Officer of Pulmatrix, commented, “Winding down the Phase 2b study for PUR1900, along with other cost-savings measures, is expected to extend Pulmatrix’s cash runway into Q1 2026. We will continue our focus on strategic alternatives that leverage the potential of PUR3100, iSPERSE™ technology and our extended cash resources.”

 

2023 and Recent Program and Corporate Highlights

 

PUR3100

 

  ● In September 2023, Pulmatrix announced the FDA’s acceptance of an IND application for PUR3100 and receipt of a “study may proceed” letter for a Phase 2 study. The IND includes a Phase 2 clinical protocol where safety and preliminary efficacy of PUR3100, an orally inhaled dihydroergotamine (DHE) engineered with iSPERSE™, will be investigated in patients with acute migraine.
     
  ● The planned Phase 2 trial builds on the Phase 1 trial results, which were published in 2023 and presented at the American Headache Society 65th Annual Meeting in June 2023. Compared to observations of nausea and vomiting in the intravenously (IV) administered DHE dose group, the PUR3100 dose groups showed a lower incidence of nausea and no vomiting. The study also showed that PUR3100 achieved peak exposures in the targeted therapeutic range and time to maximum concentration occurred at five minutes after dosing at all dosing levels.

 

PUR1800

 

  ● In February 2023, Pulmatrix presented complete results from a Phase 1b study of PUR1800 for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The results indicated PUR1800 was safe and well tolerated with no observed safety signals. The topline data, along with the results from chronic toxicology studies, support the continued development of PUR1800 for the treatment of AECOPD and other inflammatory respiratory diseases. Pulmatrix plans to pursue partnership or other alternatives to monetize or advance PUR1800.

 

 

 

 

 

PUR1900

 

  ● On January 8, 2024, in agreement with its partner Cipla, Pulmatrix announced plans to stop patient enrollment at 8 subjects in the Phase 2b study of PUR1900, effective immediately. PUR1900 is the Company’s inhaled iSPERSE™ formulation of the antifungal drug itraconazole for indications where an orally inhaled antifungal may provide a therapeutic benefit or fulfill an unmet medical need. The decision to stop the study was unrelated to any safety concerns. This study had been ongoing since the first quarter of 2023. The Company expects to complete all Phase 2b activities by the third quarter of 2024.
     
  ● After the study wind down, Pulmatrix will bear no further financial responsibility for the development of PUR1900 and will receive 2% royalties on any potential future net sales by Cipla outside the United States. Within the United States, Pulmatrix and Cipla will seek to monetize PUR1900.

 

Fourth Quarter and Year-End Financial Results

 

Revenues increased $1.2 million to $7.3 million for the year ended December 31, 2023, compared to $6.1 million for the year ended December 31, 2022. The increase is related to higher activity under the Cipla Agreement for PUR1900 during the period.

 

Research and development expenses decreased approximately $2.7 million to $15.5 million for the year ended December 31, 2023, compared to $18.2 million for the year ended December 31, 2022. The decrease was primarily due to decreased spend of $2.7 million in costs related to the Company’s PUR3100 program, $1.0 million of employment costs, and $0.7 million in costs related to the Company’s PUR1800 program, partially offset by an increase of $1.3 million in costs related to the Company’s PUR1900 program and $0.4 million of other operating costs.

 

General and administrative expenses decreased $0.3 million to $6.5 million for the year ended December 31, 2023, compared to $6.8 million for the year ended December 31, 2022. The decrease was primarily due to decreased spend of $0.7 million in employment costs, partially offset by an increase of $0.4 million in legal and professional services costs.

 

The Company’s total cash and cash equivalents balance as of December 31, 2023, was $19.2 million. The Company anticipates that its cash position, based on operational efficiencies and prioritization of spending, is sufficient to fund its operations into the first quarter of 2026.

 

 

 

 

 

PULMATRIX, INC.

Consolidated Balance Sheets

(in thousands, except share and per share data)

 

  

December 31, 2023

  

December 31, 2022

 
         
Assets          
Current assets:          
Cash and cash equivalents  $19,173   $35,628 
Restricted cash   -    153 
Accounts receivable   928    1,298 
Prepaid expenses and other current assets   742    1,068 
Total current assets   20,843    38,147 
Property and equipment, net   1,158    235 
Operating lease right-of-use asset   10,309    710 
Long-term restricted cash   1,472    1,472 
Other long-term assets   176    389 
Total assets  $33,958   $40,953 
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable  $1,915   $1,188 
Accrued expenses and other current liabilities   947    1,638 
Operating lease liability   429    857 
Deferred revenue   618    1,339 
Total current liabilities   3,909    5,022 
Deferred revenue, net of current portion   3,727    4,822 
Operating lease liability, net of current portion   8,327    - 
Total liabilities   15,963    9,844 
Stockholders’ equity:          
Preferred stock, $0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A convertible preferred stock; no shares issued and outstanding at December 31, 2023 and December 31, 2022   -    - 
Common stock, $0.0001 par value — 200,000,000 shares authorized; 3,652,285 and 3,639,185 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively   -    - 
Additional paid-in capital   305,592    304,585 
Accumulated deficit   (287,597)   (273,476)
Total stockholders’ equity   17,995    31,109 
Total liabilities and stockholders’ equity  $33,958   $40,953 

 

 

 

 

 

PULMATRIX, INC.

Consolidated Statements of Operations

(in thousands, except share and per share data)

 

  

Year Ended

December 31,

 
   2023   2022 
Revenues  $7,298   $6,071 
           
Operating expenses          
Research and development   15,518    18,240 
General and administrative   6,520    6,778 
Total operating expenses   22,038    25,018 
Loss from operations   (14,740)   (18,947)
Other income (expense)          
Interest income   867    309 
Other expense, net   (248)   (198)
Total other income (expense), net   619    111 
Net loss  $(14,121)  $(18,836)
Net loss per share attributable to common stockholders – basic and diluted  $(3.87)  $(5.46)
Weighted average common shares outstanding – basic and diluted   3,651,911    3,447,701 

 

 

 

 

 

About Pulmatrix, Inc.

 

Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company’s proprietary product pipeline includes treatments for central nervous system (“CNS”) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (“COPD”) and allergic bronchopulmonary aspergillosis (“ABPA”). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

 

For more on the Company’s inhaled product candidates please visit: 

https://www.pulmatrix.com/pipeline.html.

 

Forward-Looking Statements

 

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that”, “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the impact of the novel coronavirus (COVID-19) endemic on the Company’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on the Company’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Investor Contact:

Timothy McCarthy, CFA

917-679-9282

tim@lifesciadvisors.com

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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pulm-20240328.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 pulm-20240328_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 pulm-20240328_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 28, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 28, 2024
Entity File Number 001-36199
Entity Registrant Name PULMATRIX, INC.
Entity Central Index Key 0001574235
Entity Tax Identification Number 46-1821392
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 36 Crosby Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Bedford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01730
City Area Code (781)
Local Phone Number 357-2333
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol PULM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pulmatrix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm pulm-20240328.xsd pulm-20240328_lab.xml pulm-20240328_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "PULM", "nsuri": "http://pulmatrix.com/20240328", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "pulm-20240328.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "pulm-20240328_lab.xml" ] }, "presentationLink": { "local": [ "pulm-20240328_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://pulmatrix.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://pulmatrix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-011627-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-011627-xbrl.zip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end XML 18 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001574235 2024-03-28 2024-03-28 iso4217:USD shares iso4217:USD shares false 0001574235 8-K 2024-03-28 PULMATRIX, INC. DE 001-36199 46-1821392 36 Crosby Drive Suite 100 Bedford MA 01730 (781) 357-2333 false false false false Common Stock, par value $0.0001 per share PULM NASDAQ false